STAAR Surgical Company (STAA)
Official siteHEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NASDAQ
Market Cap: $1.32B
Last updated: Nov 17, 2026 at 11:05 AM ET
STAAR Surgical Company (STAA) Financials: Revenue, Profit and Cash Flow
STAAR Surgical Company reported revenue of $239.44M for the fiscal year ended Dec 31, 2025, down 23.7% from the year before. That year, net income was -$80.45M with a net margin of -33.6%, operating cash flow was -$34.23M and free cash flow was -$40.05M. The quarter ended Sep 30, 2026 had revenue of $83.41M and net income of $5.58M.
Revenue and Margins
The operating margin was -38.3% in the fiscal year ended Dec 2025, the lowest of the 10 years shown. Over the 9 years to Dec 2025, revenue grew from $82.43M, a compound annual rate of 12.6%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $239.44M | -23.7% | 76.2% | -38.3% | -33.6% |
| Dec 2024 | $313.90M | -2.6% | 76.3% | -4.0% | -6.4% |
| Dec 2023 | $322.42M | +13.4% | 78.4% | 8.7% | 6.6% |
| Dec 2022 | $284.39M | +23.4% | 78.5% | 15.4% | 13.9% |
| Dec 2021 | $230.47M | +41.0% | 77.5% | 14.5% | 11.9% |
| Dec 2020 | $163.46M | +8.8% | 72.4% | 4.1% | 3.6% |
| Dec 2019 | $150.19M | +21.2% | 74.5% | 7.9% | 9.4% |
| Dec 2018 | $123.95M | +36.8% | 73.8% | 5.3% | 4.0% |
| Dec 2017 | $90.61M | +9.9% | 70.9% | -4.0% | -2.4% |
| Dec 2016 | $82.43M | N/A | 70.8% | -15.4% | -14.7% |
Income Statement
In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, net income fell 37.2% from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $239.44M | $313.90M | $322.42M | $284.39M | $230.47M | $163.46M | $150.19M | $123.95M | $90.61M | $82.43M |
| Cost of revenue | $57.02M | $74.32M | $69.76M | $61.01M | $51.84M | $45.10M | $38.23M | $32.44M | $26.33M | $24.06M |
| Gross profit | $182.42M | $239.58M | $252.65M | $223.38M | $178.64M | $118.36M | $111.95M | $91.51M | $64.28M | $58.37M |
| Research and development | $40.05M | $45.32M | $40.48M | $35.98M | $33.86M | $31.92M | $25.30M | $22.03M | $20.04M | $20.67M |
| Operating income | -$91.71M | -$12.61M | $28.10M | $43.80M | $33.34M | $6.77M | $11.85M | $6.59M | -$3.63M | -$12.65M |
| Net income | -$80.45M | -$20.21M | $21.35M | $39.66M | $27.51M | $5.91M | $14.05M | $4.97M | -$2.14M | -$12.13M |
| EBITDA | -$78.13M | -$8.58M | $31.76M | $46.81M | $33.97M | $10.68M | $15.19M | $8.30M | $589.00K | -$10.06M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $83.41M | $93.53M | $93.52M | $57.80M | $94.73M | $44.32M | $42.59M | $48.95M | $88.59M | $99.00M | $77.36M | $76.27M |
| Gross profit | $59.13M | $69.73M | $68.86M | $43.74M | $77.88M | $32.80M | $28.00M | $31.65M | $68.49M | $78.41M | $61.03M | $60.73M |
| Operating income | $5.46M | $10.10M | $7.98M | -$22.84M | $18.49M | -$29.96M | -$57.40M | -$27.91M | $5.68M | $11.90M | -$2.28M | $10.40M |
| Net income | $5.58M | $8.06M | $5.21M | -$18.31M | $8.88M | -$16.81M | -$54.21M | -$34.23M | $9.98M | $7.38M | -$3.34M | $7.76M |
Balance Sheet
As of Dec 2025, cash and equivalents exceeded short-term debt of $5.87M by $147.28M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $451.68M | $509.52M | $488.69M | $418.82M | $345.78M | $257.42M | $207.52M | $167.34M | $67.93M | $65.48M |
| Current assets | $311.55M | $367.94M | $365.27M | $311.72M | $271.41M | $216.42M | $174.67M | $151.57M | $53.89M | $49.52M |
| Cash and equivalents | $153.15M | $144.16M | $183.04M | $86.48M | $199.71M | $152.45M | $119.97M | $103.88M | $18.52M | $14.00M |
| Total liabilities | $107.49M | $112.19M | $102.74M | $82.71M | $87.22M | $60.19M | $47.64M | $34.91M | $25.00M | $27.57M |
| Short-term debt | $5.87M | $3.94M | $4.37M | $3.69M | $3.41M | $1.38M | $1.83M | $3.78M | $5.72M | $5.48M |
| Long-term debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $531.00K | $1.34M |
| Shareholder equity | $344.18M | $397.33M | $385.95M | $336.11M | $258.56M | $197.22M | $159.88M | $132.43M | $42.94M | $37.91M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $485.16M | $475.20M | $451.12M | $461.62M | $456.36M | $437.78M | $457.36M | $509.52M | $537.59M | $512.75M | $492.54M | $488.69M |
| Total liabilities | $109.03M | $109.81M | $98.75M | $117.44M | $102.58M | $101.21M | $107.39M | $112.19M | $109.47M | $103.64M | $99.75M | $102.74M |
| Cash and equivalents | $133.61M | $148.58M | $131.86M | $153.15M | $176.16M | $167.13M | $173.11M | $144.16M | $164.00M | $192.78M | $224.02M | $183.04M |
| Shareholder equity | $376.13M | $365.40M | $352.37M | $344.18M | $353.78M | $336.57M | $349.97M | $397.33M | $428.12M | $409.10M | $392.79M | $385.95M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Dec 2025.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$34.23M | $15.72M | $14.59M | $35.72M | $43.96M | $20.95M | $25.80M | $12.77M | $2.85M | $1.05M |
| Capital expenditures | $5.82M | $23.39M | $18.19M | $18.11M | $13.64M | $8.40M | $10.10M | $2.25M | $1.05M | $3.21M |
| Free cash flow | -$40.05M | -$7.67M | -$3.59M | $17.61M | $30.32M | $12.55M | $15.70M | $10.52M | $1.81M | -$2.16M |
| Dividends paid | N/A | N/A | $9.67K | N/A | N/A | N/A | N/A | $5.20M | $3.97M | $3.98M |
| Share repurchases | $6.46M | $0 | $0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing cash flow | $46.34M | -$59.22M | $74.35M | -$156.38M | -$13.64M | -$8.40M | -$10.18M | -$2.25M | -$1.05M | -$3.21M |
| Financing cash flow | -$4.55M | $5.72M | $7.42M | $8.30M | $17.79M | $19.57M | $149.00K | $74.64M | $2.44M | $2.95M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $27.32M | $19.69M | -$21.70M | -$3.91M | $2.67M | -$27.25M | -$5.73M | $642.00K | $3.82M | -$10.41M | $21.68M | $31.97M |
| Capital expenditures | $935.00K | $494.00K | $443.00K | $1.68M | $883.00K | $1.79M | $1.47M | $5.72M | $6.23M | $6.24M | $5.20M | $3.09M |
| Free cash flow | $26.38M | $19.20M | -$22.14M | -$5.59M | $1.78M | -$29.04M | -$7.20M | -$5.08M | -$2.42M | -$16.65M | $16.48M | $28.88M |
Frequently Asked Questions About STAA
What is STAAR Surgical Company's annual revenue?
STAAR Surgical Company reported revenue of $239.44M for the fiscal year ended Dec 31, 2025.
How fast is STAAR Surgical Company's revenue growing?
Revenue was down 23.7% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was -5.6%.
Is STAAR Surgical Company profitable?
No. STAAR Surgical Company reported net income of -$80.45M for the fiscal year ended Dec 31, 2025, with a net margin of -33.6%.
How much free cash flow does STAA generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of -$34.23M minus capital expenditures of $5.82M produced free cash flow of -$40.05M.
How much debt does STAAR Surgical Company have?
The balance sheet dated Dec 31, 2025 reported short-term debt of $5.87M and cash and equivalents of $153.15M.
STAA pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts